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Summary A total of 152 non-small cell lung cancers (NSCLC) were studied retrospectively to determine the
relationship between epidermal growth factor receptor (EGF-R) status and the histological type, tumour size,
nodal status and prognosis. EGF-R status was assessed on routinely embedded paraffin sections with an
antibody to the cytoplasmic domain of the tumour (F4 antibody). EGF was demonstrated in all tumour
types and every squamous and large cell carcinoma was positive for the antibody. Most tumours showed
heterogeneity of staining. EGF expression was seen statistically more frequently in well differentiated
tumours. Patients with 50% or more tumour cells showing positivity tended to have an improved survival but
this result failed to reach statistical significance. There was no relationship between the size of the primary
tumour or the lymph node status. Other cells, such as mucinous glands, bronchial epithelial cells and
macrophages stained positively with the monoclonal antibody. EGF receptor status, with the antibodies
presently available, adds little to help in either diagnosis or prognosis. Interpretation of data has to be
guarded since the antibody was seen in some normal cells.
Lung cancer is often divided into two main groups: small
cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC). NSCLC represents a mixed group of tumours
with some distinctive, but overlapping, histological, clinical
and biological characteristics. There is a need to identify
features which can predict tumour behaviour and allow
better prognostic evaluation. The best therapy, with the least
toxicity, can then be given and the biological properties of
NSCLC understood.
Recently it has become apparent that cancer cells are able
to produce and respond to their own growth factors. One
such factor is epidermal growth factor (EGF), first purified
from the submandibular gland of male mice and described
by Cohen (1962). EGF is found in almost all body fluids
under normal physiological conditions (Carpenter &
Zendegui, 1986). It is known to promote cell proliferation
while inhibiting terminal differentiation and conversely can
cause dose dependent inhibition of cell proliferation.
Different aspects of growth and differentiation were
described in certain cell culture models and in vivo, following
EGF treatment (Cohen, 1982; Gusterson et al., 1984; Ozanne
et al., 1986). The specific receptor for EGF (EGF-R), first
purified from the A431 cell line, is a 170,000kDa trans-
membrane glycoprotein. An extracellular domain is capable
of binding the ligand, EGF or transforming growth factor
(TGF) alpha, with a transmembrane function and an intra-
cellular domain facing the cytoplasm. EGF-R is found on
the surface of many cells, including normal and malignant
cells of epidermal or mesenchymal origin but not in cells of
the haematopoietic system (Carpenter & Cohen, 1979;
Cowley et al., 1984; Gullick et al., 1986; Real et al., 1986).
The function of EGF-R is to bind the mitogen EGF or TGF
alpha and to transduce the signal across the cell membrane to
the cytoplasm. The intracellular part exhibits the tyrosine
kinase function and presumably has binding sites for ATP
(Cohen et al., 1982). A close similarity between sequences of
the v-erb-B oncogene of AEV-H and the truncated EGF-R
has been found (Downward et al., 1984).
The aim of the present study was to analyse the clinico-
pathological significance of EGF-R expression determined
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by the monoclonal F4 antibody in NSCLC archival material.
The presence of EGF-R was related to tumour stage, various
histological characteristics and the clinical outcome.
Materials and methods
Patients
Paraffin embedded samples obtained at thoracotomy from
one surgeon (R.A.M.L.) were analysed. Minimum patient
follow-up time is 3 years. Tumours were classified according
to the histological subgroups recommended by the WHO
(1981). The grade of differentiation, nodal involvement and
where possible tumour size (in surgically resected specimens)
were also noted.
Methods
Expression of EGF-R was detected immunohistochemically
by the monoclonal antibody, MoAb F4. This antibody was
produced to a synthetic peptide consisting of residues 985-
996 from the complete EGF-R sequence of 1206, and
therefore is just outside the region of sequence homology
shared by the scr oncogene family (Gullick et al., 1986). It
was kindly supplied by Dr W.J. Gullick, Imperial Cancer
Research Fund Laboratories, London.
Sections 5pm were cut from paraffin blocks and dewaxed
in xylene for 10min followed by rehydration in decreasing
alcohol concentrations (100%, 95%, 90% and 70%
respectively) and water, and finally washed in Tris buffered
saline (TBS 0.5M, pH 7.0). The sections were pre-incubated
for 10min with normal rabbit immunoglobulin serum
(Dakopatts, Denmark) diluted in TBS 1:5. The excess was
washed off in TBS for 5min. Then the sections were covered
with the MoAb F4 at a concentration of 1:50 in diluted
normal rabbit immunoglobulin and incubated overnight at
4°C. Subsequent layers consisted of a rabbit anti-mouse
immunoglobulin Z259 (Dakopatts) at a concentration of
1:25 in diluted normal rabbit serum for 30min at room
temperature and the excess washed off in TBS for 5min. A
1:50 dilution gave 0.006mgml-1 of stock antibody. The
sections were then immediately incubated with monoclonal
mouse APAAP D651 (Dakopatts) also at a concentration of
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1:25 in diluted rabbit serum for 30min at room temperature
and excess washed off in TBS for 5min. To increase the
intensity of staining the last two steps were repeated. Finally
the red enzyme reaction was developed with Naphthol AS
Biphosphate and Fast Red in TBS 0.1 M pH 8.2 with 1 mM
Levamisole to block endogenous alkaline phosphatase. The
sections were then incubated for 20min at room
temperature. Finally the sections were washed in TBS and
water and counterstained in Haematoxylin for 5min.
For controls, two sections of normal skin were used in
each run. One of the sections was incubated with the MoAb
F4 and for a negative control the other was incubated with
non-specific immunoglobulin. Otherwise the control sections
were processed as described above. Inter and intra-assay
consistency was monitored by the inclusion of the two
control sections of normal skin. Any assay in which either
control was unsatisfactory was repeated. A further control
was competition of staining of EGF-F4 by free peptide 2E at
a concentration of 1.0mgml-1 (obtained by courtesy of Dr
Gullick). Free peptide was diluted 1: 10 to a concentration of
0.1 mgml-1 and placed in a test tube with an equal volume
of EGF-F4 at a 1:50 dilution. This was allowed to stand for
3 h at room temperature then placed along with EGF-F4 on
a control section of skin and incubated overnight at 4°C.
After scanning on low power, 20 high power fields ( x 10
eyepiece, x 40 objective) of the tumour were examined. The
number of positively stained cells (but not the intensity of
the staining) was estimated. Results were expressed as four
groups, i.e. EGF-R -ve (0-4%), EGF-R +ve (5-19%),
EGF-R + +ve (20-49%) and EGF-R + + +ve (>50%).
Results
A total of 152 tumours were analysed. They consisted of 97
squamous cell, 31 adeno, seven large cell and 17 undifferen-
tiated non-small cell carcinomas. There were 117 male and
35 female patients with a median age of 59 (range 38-75
years).
Fifty-five per cent squamous cell carcinomas stained very
strongly for EGF-R (++ +ve) (Figure 1). The corresponding
value for adenocarcinoma was 45% (Figure 2), large cell
43% and undifferentiated carcinomas 29%. A x2 analysis
of the distribution of EGF-R positivity and histology
revealed no significant difference (P>0.5). The small number
of patients negative for EGF-R were unsuitable for inclusion
in the analysis. In every tumour of the squamous and large
cell types some of the cells stained positively for EGF-R.
However, three out of 17 undifferentiated non-small cell
cancers did not stain for EGF-R (see Table I).
EGF-R, visualised by using the MoAb F4, was cyto-
plasmic. Heterogeneity of tumour staining was present in
95% of tumours. In some specimens a clear difference was
seen in the positivity of the EGF-R -between central and
peripheral tumour cells. Peripheral cells were more often
positive. In other cases no difference in the number of cells
positive for EGF-R between the centre of the tumour and
the periphery was observed. However, clusters of intensely
stained tumour cells were next to cells with faint or no
staining for EGF-R (Figure 2). The heterogeneity of
EGF-R staining had no obvious correlation to the tumour
morphology as assessed by routine Haematoxylin and Eosin.
When EGF-R expression in tumours was compared with
the grade of differentiation significant differences were
observed. Of the well differentiated tumours 81% were very
strongly positive (EGF-R + + +ve) compared with 43-50%
for less differentiated tumours, and only 29% for the
undifferentiated group (see Table II). A separate analysis
comparing EGF-R positivity in the differentiated and the
undifferentiated tumour groups was also significantly
different (P=0.0032, Fisher's exact test). There was no clear
difference between EGF receptor status and size of the
primary tumour or the presence of regional nodal
involvement (see Tables III and IV).
Figure 1 Squamous cell carcinoma staining positivity with EGF
F4.
Figure 2 Adenocarcinoma of lung showing focal positivity.
Figure 3 Staining surface microvilli with EGF in bronchial wall.
Table I EGF-R positivity and histology
Number and (percentage) of tumours
(EGF-R)
Patient
Histology number -ve +ve + +ve + + +ve
Squamous 97 0 11 (11) 33 (34) 53 (55)
Adenocarcinoma 31 1 (3) 1 (3) 15 (49) 14 (45)
Large cell 7 0 1 (14) 3 (43) 3 (43)
Undifferentiated 17 3 (18) 2 (12) 7 (41) 5 (29)
Total 152 4 15 58 75
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Table II EGF-R positivity and histological differentiation
Number and (percentage) of tumours
(EGF-R)
Patient
Differentiation number -ve +ve + +ve + ++ ve
Well 21 1 (5) 0 3 (14) 17 (81)
Moderate 58 0 5 (9) 24 (41) 29 (50)
Poor 56 0 8 (14) 24 (43) 24 (43)
Undifferentiated 17 3 (18) 2 (12) 7 (41) 5 (29)
Total 152 4 15 58 75
P=0.0436, x2 analysis (excluding the 4 EGF-R -ve tumours).
Table III EGF-R positivity and primary tumour size
Number and (percentage) of tumours
(EGF-R)
Patient
Primary tumour number -ve +ve + +ve ++ +ve
TI (<3cm) 11 0 2 (18) 4 (36) 5 (46)
T2 (>3cm) 46 4 (9) 2 (4) 13 (28) 27 (59)
Table IV EGF-R positivity and nodal involvement
Number and (percentage) of tumours
(EGF-R)
Lymph node Patient
infiltration number -ve + ve + + ve + ++ ve
Yes 47 3 (6) 5 (11) 14 (30) 25 (53)
No 44 4 (9) 5 (11) 16 (37) 19 (43)
Control sections of normal skin demonstrated positive
staining in the epidermis but when the F4 antibody was
omitted no staining was seen. A large variety of normal cells
also had positive staining for EGF-R, e.g. macrophages,
serous and mucinous glands as well as bronchiolar epithelial
cells, smooth muscle, endothelium and nerves (Figure 3).
Rather unexpectedly in cartilage there was EGF-R staining
in the bipolar areas of the nuclei. Necrotic tumour areas
exhibited, in particular, a very intense but non-specific
staining (Fast Red control stains were also positive). In the
control sections of skin treated with antiserum, consisting of
EGF-F4 that had been left to compete with free peptide 2E
there was no staining of the epidermis but positive staining
was seen in the EGF-F4 sections.
Survival
Patients with tumours exhibiting 50% or more of cellular
staining for EGF-R (+ + +ve) tended to have an improved
survival, but this was not statistically significant (log rank
analysis P>0.05). However, patients with well differentiated
tumours did have a significantly increased survival compared
with patients whose tumours were moderately, poorly or
undifferentiated (log rank analysis P=0.04) (Figure 4).
Discussion
The present study was carried out to see if the EGF receptor
status had any effect on the prognosis in non-small cell lung
cancer. Unfortunately, even though this is one of the largest
series of lung tumours stained with EGF-R the figures failed
to reach statistical significance. There was, however, a trend
that patients with tumours showing 50% of more staining
for EGF-R (+ + +ve) did show increased survival. It is likely
that had more cases of squamous cell carcinoma been
studied that a significant result would have been achieved,
especially in light of the fact that well differentiated tumours
have a significantly increased survival compared with
patients whose tumours were moderately, poorly or undif-
ferentiated. As far as we are aware the only previous paper
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Figure 4 Correlation of survival with EGF receptor status.
to address the concept of EGF receptor status in non-small
cell lung cancer and prognosis is that of Veale et al. (1987).
These authors, however, related EGF receptor status to the
stage of disease. These authors noted significantly stronger
staining in 30 stage 3 tumours compared with 47 stage I and
stage 2 tumours. This result was statistically significant.
They, however, found no significant difference in the number
of stage 3 squamous tumours (17 out of 40) compared with
the number of stage 3 adeno and large cell carcinomas.
There was also a suggestion that the larger tumours (>3cm)
had more positive tumour cells. The findings could be
related to the fact that well differentiated tumours had a
significantly greater number of positive cells and such
patients had a longer survival time. In our study, unlike that
of Veale et al. (1987), there was a tendency to greater
positivity in EGF-R well differentiated tumours than poorly
differentiated ones.
However, EGF-R expression in normal and malignant
transformed cells does not always provide information
concerning proliferation. Not all cell types positive for
EGF-R demonstrate a biological response to the growth
factor (Carpenter & Zendegui, 1986). EGF-R expression may
in some tissues be more related to specific stages of dif-
ferentiation. This would be compatible also with the present
observations where well differentiated tumours were signifi-
cantly more EGF-R positive than tumours of lesser
differentiation.
Comparison of our present study with previous investi-
gations of EGF receptors in non-small cell lung cancer is
difficult. This is because previous studies including our own
(Cerny et al., 1986; Hendler & Ozanne, 1984; Veale et al.,
1987; Sobol et al., 1987; Berger et al., 1987) all used fresh
tumour tissue. In these studies a different anti-serum was
used, i.e. EGF-RI. Our previous study (Cerny et al., 1986)
and the study of Berger et al. (1987) showed that EGF-R1,
which can only be carried out on frozen sections, was a
more sensitive anti-serum than EGF-F4. We have noted
along with Berger that F4 staining is less intense in paraffin
than frozen sections and this may explain some of the
discrepancies between our results and the authors quoted
above. It should be noted, however, that Berger with the F4
antibody obtained 72% of squamous carcinomas positive for
EGF-F4 (our figures 64%), 28.5% adenocarcinomas (our
figures 31%), 33% of large cell carcinomas (our figures
27%). However, while F4 is not as good an antibody and
may give some background staining not seen with the Rl
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antibody, it is important to note that the use of frozen
sections does limit the studies that can be performed retro-
spectively. The rationale of the present study was to
determine prognosis in relation to the known minimal 3-year
follow-up in non-small cell lung cancer. In a current study
(Dazzi et al., unpublished) we found only a slight discre-
pancy between the numbers of cells staining with the RI and
F4 antibody in NSCLC. It is important to note that the RI
antibody is detecting the extracellular domain of EGF
receptor whereas the F4 antibody is directed at the cytoplas-
mic region of EGF. It should be noted from previous studies
(Cerny et al., 1986; Berger et al., 1987) that although MoAb
F4 may give less intense staining than MoAb RI it identifies
the same cells as being positive.
The present study has enabled us to show that EGF
receptor status is not confined to squamous cell carcinoma
of the lung as originally thought by Hendler and Ozanne
(1984). In common with other authors (Cerny et al., 1986;
Veale et al., 1987; Berger et al., 1987) we found staining for
this receptor in adenocarcinoma as well as large cell
carcinoma. However, EGF is most commonly expressed in
squamous cell carcinomas. Some of the above differences in
staining of cell types could be due to the cellular hetero-
geneity noted in lung cancer (Minna et al., 1985). One might
therefore expect a difference in expression in EGF-R within
a particular tumour type and even within one patient's
tumour.
A feature of the present study was that EGF-R status was
significantly different in differentiated tumours from in
undifferentiated carcinomas. This finding is at variance with
that of Veale et al. (1987), who showed no significant
difference in the intensity of staining for EGF-R between the
groups of tumours when divided into well and moderately
differentiated versus poorly differentiated carcinomas.
Another feature of the present study is the presence of
EGF-R on normal bronchial basal epithelial cells and cells
of serous and mucinous glands. There cells are normally
proliferating. However, the lung cancer cell often is not fully
differentiated and may lose the expression of specific
receptors but can continue to proliferate (Kaplan et al.,
1982; Moses et al., 1978). Our observations suggest that in
well differentiated NSCLC the tumours are biologically
similar to their normal cell of origin and therefore, as
expected, will still express the EGF-R in a high percentage
of tumour cells.
In contrast to normal lung tissue (bronchial epithelium,
mucinous and serous glands, cartilage) non-malignant breast
and bladder tissue do not normally express the EGF-R
(Spitzer et al., 1987; Neal et al., 1985). Overexpression of
EGF-R could be a feature of malignant transformation of
the latter two organs and therefore be capable of being
recognised as having prognostic significance (Berger et al.,
1987; Neal et al., 1985; Fitzpatrick et al., 1984; Sainsbury et
al., 1987; Spitzer et al., 1987).
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